Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,742.33
(
0.64%
)
US TECH 100
24,214.00
(
0.83%
)
Dow Jones
47,278.04
(
0.71%
)
Brent Oil
100.13
(
1.86%
)
Bitcoin
73,789.99
(
-1.41%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 134686

Thursday, 04/19/2012 10:37:27 PM

Thursday, April 19, 2012 10:37:27 PM

Post# of 257251
Presidio provides update on its NS5A inhibitor, PPI-668:

http://finance.yahoo.com/news/presidio-pharmaceuticals-announces-phase-1a-040000825.html

PPI-668 is the successor to PPI-461, a drug that Presidio acquired from XTLB at a firesale price about four years ago (#msg-27791536).

p.s. If XTLB had waited until now to sell a preclinical NS5A inhibitor, they probably could have walked away with real money :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now